These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18218291)

  • 1. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
    Séchaud R; Dutreix C; Balez S; Pommier F; Dumortier T; Morisson S; Brun E
    Int J Clin Pharmacol Ther; 2008 Feb; 46(2):102-8. PubMed ID: 18218291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.
    Séchaud R; Robeva A; Belleli R; Balez S
    J Clin Pharmacol; 2008 Aug; 48(8):919-25. PubMed ID: 18508948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
    Galanello R; Piga A; Cappellini MD; Forni GL; Zappu A; Origa R; Dutreix C; Belleli R; Ford JM; Rivière GJ; Balez S; Alberti D; Séchaud R
    J Clin Pharmacol; 2008 Apr; 48(4):428-35. PubMed ID: 18281442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers.
    Bladh N; Blychert E; Johansson K; Backlund A; Lundin C; Niazi M; Pettersson G; Fjellman M
    Clin Ther; 2007 Apr; 29(4):640-9. PubMed ID: 17617287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
    Sechaud R; Robeva A; Belleli R; Balez S
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):519-26. PubMed ID: 18826866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
    Chauzit E; Bouchet S; Micheau M; Mahon FX; Moore N; Titier K; Molimard M
    Ther Drug Monit; 2010 Aug; 32(4):476-81. PubMed ID: 20386360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of deferasirox.
    Tanaka C
    Clin Pharmacokinet; 2014 Aug; 53(8):679-94. PubMed ID: 24996374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The palatability and tolerability of deferasirox taken with different beverages or foods.
    Goldberg SL; Giardina PJ; Chirnomas D; Esposito J; Paley C; Vichinsky E
    Pediatr Blood Cancer; 2013 Sep; 60(9):1507-12. PubMed ID: 23637051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
    Sechaud R; Dumortier T; Balez S
    Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
    Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
    Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions.
    Gao X; Ndongo MN; Checchio TM; Cook J; Duncan B; LaBadie RR
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):74-80. PubMed ID: 27128005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration diluents differentiate Neoral from a generic cyclosporine oral solution.
    Kovarik JM; Barilla D; McMahon L; Wang Y; Kisicki J; Schmouder R
    Clin Transplant; 2002 Aug; 16(4):306-9. PubMed ID: 12099989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.
    Weiss HM; Fresneau M; Camenisch GP; Kretz O; Gross G
    Drug Metab Dispos; 2006 Jun; 34(6):971-5. PubMed ID: 16531476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.